Immix Biopharma (IMMX)

Executive Summary

Immix Biopharma is a clinical-stage biotechnology company focused on developing novel therapies for relapsed/refractory AL amyloidosis and solid tumors. Its lead candidate, NXC-201, a CAR-T cell therapy targeting BCMA, has demonstrated encouraging efficacy and safety in a Phase 1/2 trial for AL amyloidosis, as highlighted by an oral presentation at ASH 2025. The company also has IMX-110, a nanoparticle-based drug candidate for advanced solid tumors, currently in Phase 1/2. Given the high unmet need in AL amyloidosis and the positive early data, Immix is positioned to advance its pipeline toward potential registration. However, reliance on a single late-stage asset and the inherent risks of CAR-T therapies temper conviction.

Upcoming Catalysts (preview)

• Q2 2026NXC-201 Phase 2 interim data update in AL amyloidosis (potential at ASCO or EHA 2026)70% success
• Q3 2026FDA meeting to discuss accelerated approval pathway for NXC-20160% success
• H2 2026IMX-110 Phase 1/2 dose escalation data in solid tumors50% success